EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Folic Acid-Modified Ibrutinib-Loaded Silk Fibroin Nanoparticles for Cancer Cell Therapy with Over-Expressed Folate Receptor

Marta G Fuster iD, Mercedes G Montalbán iD, Imane Moulefera iD, Gloria Víllora iD, David L Kaplan iD

Pharmaceutics · 07.04.2023 · 15 (4) · 1186

DOI: 10.3390/pharmaceutics15041186 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 07.04.2023. Verfasst von Marta G Fuster und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Engineering, Faculty of Chemistry, University of Murcia (UMU), Campus de Espinardo, 30100 Murcia, Spain. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MCIN/AEI/ 10.13039/501100011033, NextGenertionEU, MCIN/AEI/10.13039/501100011033.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The anticancer drug ibrutinib (IB), also known as PCI-32765, is a compound that irreversibly inhibits Bruton’s tyrosine kinase (BTK) and was initially developed as a treatment option for B-cell lineage neoplasms. Its action is not limited to B-cells, as it is expressed in all hematopoietic lineages and plays a crucial role in the tumor microenvironment. However, clinical trials with the drug have resulted in conflicting outcomes against solid tumors. In this study, folic acid-conjugated silk nanoparticles were used for the targeted delivery of IB to the cancer cell lines HeLa, BT-474, and SKBR3 by exploiting the overexpression of folate receptors on their surfaces. The results were compared with those of control healthy cells (EA.hy926). Cellular uptake studies confirmed total internalization of the nanoparticles functionalized by this procedure in the cancer cells after 24 h, compared to nanoparticles not functionalized with folic acid, suggesting that cellular uptake was mediated by folate receptors overexpressed in the cancer cells. The results indicate that the developed nanocarrier can be used for drug targeting applications by enhancing IB uptake in cancer cells with folate receptor overexpression.

Schlagwörter

Stichwörter der Autor:innen

BT-474EA.hy926HeLaSKBR3cancerfolate receptoribrutinibnanoparticlessilk fibroin

Autor:innen und Institutionen

  • Department of Chemical Engineering, Faculty of Chemistry, University of Murcia (UMU), Campus de Espinardo, 30100 Murcia, Spain.
  • Department of Biomedical Engineering, Tufts University, Medford, MA 02155, USA.

ORCID-Profile: Marta G Fuster, Mercedes G Montalbán, Imane Moulefera, Gloria Víllora, David L Kaplan

Förderung

  • MCIN/AEI/ 10.13039/501100011033
  • NextGenertionEU
  • MCIN/AEI/10.13039/501100011033
  • NextGenerationEU

Zitieren

APA

Fuster, M. G., Montalbán, M. G., Moulefera, I., Víllora, G., & Kaplan, D. L. (2023). Folic Acid-Modified Ibrutinib-Loaded Silk Fibroin Nanoparticles for Cancer Cell Therapy with Over-Expressed Folate Receptor. Pharmaceutics, 15(4), 1186. https://doi.org/10.3390/pharmaceutics15041186

Vancouver

Fuster MG, Montalbán MG, Moulefera I, Víllora G, Kaplan DL. Folic Acid-Modified Ibrutinib-Loaded Silk Fibroin Nanoparticles for Cancer Cell Therapy with Over-Expressed Folate Receptor. Pharmaceutics. 2023;15(4):1186. doi:10.3390/pharmaceutics15041186

BibTeX
@article{Fuster2023,
  author = {Fuster, Marta G and Montalbán, Mercedes G and Moulefera, Imane and Víllora, Gloria and Kaplan, David L},
  title = {Folic Acid-Modified Ibrutinib-Loaded Silk Fibroin Nanoparticles for Cancer Cell Therapy with Over-Expressed Folate Receptor},
  journal = {Pharmaceutics},
  year = {2023},
  volume = {15},
  number = {4},
  pages = {1186},
  doi = {10.3390/pharmaceutics15041186}
}
Kostenlos starten →